PROJECT

Projects

Summary of Investment Information

Project Number

48236

Company Name

Shanghai Desano Bio-pharmaceutical Co., Ltd.

Date SPI Disclosed

Jul 22, 2024

Country

China

Region

East Asia and the Pacific

Projected Board Date

Jun 4, 2024

Environmental Category

B - Limited

Status

Active

Last Updated Date

Oct 25, 2025

Department

Regional Industry - MAS Asia & Pac

Industry

other

Previous Events

Approved : Jun 4, 2024
Signed : Jun 8, 2024
Invested : Dec 16, 2024

Sector

other

Project Description

Shanghai Desano Bio-Pharmaceutical Co., Ltd (“Desano”, “the Company”) is a leading Active Pharmaceutical Ingredients (“API”) and Finished Dosage Formulation (“FDF”) manufacturer in China, focusing on producing antiretroviral (“ARV”) drugs to address the global public health challenge of Human Immunodeficiency Viruses (“HIV”).

The proposed investment is a US$100 million equivalent A loan to the Company’s subsidiaries to support: (i) the construction of a new API/FDF manufacturing facility in Bangalore, India, and (ii) the expansion of an existing API manufacturing facility in Jiangxi Province, China (a frontier region), for ARV drugs targeting low- and middle-income countries (the “Project”). The Project intends to play a key role in reducing the treatment cost of HIV patients globally and enhancing the resilience of pharmaceutical supply chain through localized production.

                                                   

Sponsor / Cost / Location

Development Impact

E&S Category Rationale / Risks and Mitigation